These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25605253)

  • 1. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
    Seo SK; Hwang CS; Choe TB; Hong SI; Yi JY; Hwang SG; Lee HG; Oh ST; Lee YH; Park IC
    Oncotarget; 2015 Sep; 6(28):26528-40. PubMed ID: 25605253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
    Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
    Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
    Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
    Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells.
    Jin L; Li C; Xu Y; Wang L; Liu J; Wang D; Hong C; Jiang Z; Ma Y; Chen Q; Yu F
    Oncol Rep; 2013 May; 29(5):1983-90. PubMed ID: 23483203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
    Sun D; Yu M; Li Y; Xing H; Gao Y; Huang Z; Hao W; Lu K; Kong C; Shimozato O; Ozaki T; Zhu Y
    FEBS Open Bio; 2019 Mar; 9(3):478-489. PubMed ID: 30868056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
    Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
    J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.
    Stojanovic N; Hassan Z; Wirth M; Wenzel P; Beyer M; Schäfer C; Brand P; Kroemer A; Stauber RH; Schmid RM; Arlt A; Sellmer A; Mahboobi S; Rad R; Reichert M; Saur D; Krämer OH; Schneider G
    Oncogene; 2017 Mar; 36(13):1804-1815. PubMed ID: 27721407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
    Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
    Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
    de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
    J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
    Zhang L; Wang G; Wang L; Song C; Leng Y; Wang X; Kang J
    Mol Cell Biochem; 2012 Feb; 361(1-2):39-45. PubMed ID: 21959976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
    Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
    FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2.
    Joo HM; Kim JY; Jeong JB; Seong KM; Nam SY; Yang KH; Kim CS; Kim HS; Jeong M; An S; Jin YW
    Eur J Cell Biol; 2011 May; 90(5):420-31. PubMed ID: 21333377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
    Yang H; Zheng Z; Zhao LY; Li Q; Liao D
    Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.
    Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
    Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
    Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.
    Lau R; Niu MY; Pratt MA
    Cell Cycle; 2012 Nov; 11(21):4009-19. PubMed ID: 23032264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.